← 프로그램 목록
세포·유전자 치료Phase 2Recruiting

CD19+22 CAR-T cells

Minsk Scientific-Practical Center for SurgeryTransplantationHematology

비교

CD19+22 CAR-T cells(Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology)은 CD19 표적 세포·유전자 치료로, Acute Lymphobkastic Leukemia; B Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 1% (ClinicalTrials.gov NCT03287817). 차별점: novel autologous bispecific CAR targeting CD19 and CD22 (CAR19-22), which was well tolerated and associated with high respons.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 18일 (8일 전)PK/독성 2026년 7월 18일 (8일 전)

CD19

Acute Lymphobkastic Leukemia; B Cell Lymphoma

Recruiting

Technology

구조모아 · StructureMoa에서 구조 검색

CAR T cells in children, adolescents and young adults with B-ALL:

lentiviral cotransduction with vectors encoding our previously described fast-off rate CD1

humanized mice, led to development of a novel bicistronic CD19

novel autologous bispecific CAR targeting CD19 and CD22 (CAR19-22), which was well tolerated and associated with high respons

Mechanism of Action

targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen

cytokine release syndrome (CRS); only 2 (10%) were grade > 3

CD19 and CD22 (CAR19-22), which was well tolerated and associated with high

escape observed after single antigen targeting therapy

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 33건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 1, Phase 2 · Phase 2 · Phase 1…
  • Status: Active, not recruiting · Not yet recruiting · Recruiting
  • 주요 endpoint: Progression-free Survival (PFS) as Assessed by Blinded Central Assessment per Lugano Classification · Overall Survival (OS) · Complete Response (CR) Rate as Assessed by Blinded Central Assessment per Lugano Classification · Objective Response Rate (ORR) as Assessed by Blinded Central Assessment per Lugano Classification · Duration of Response (DOR) as Assessed by Blinded Central Assessment per Lugano Classification
  • 등록된 결과: ORR 1%
  • PFS: 2.14
  • 핵심: The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 wi…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

CD19+22 CAR-T cells은 어떤 치료제인가요?
CD19+22 CAR-T cells(Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology)은 CD19 표적 세포·유전자 치료로, Acute Lymphobkastic Leukemia; B Cell Lymphoma 영역에서 개발·상용화 중입니다. 데이터는 바이오정보모아 (BioJungboMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
CD19+22 CAR-T cells의 임상 단계는?
CD19+22 CAR-T cells의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오정보모아 (BioJungboMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.